Greenwich LifeSciences Stock Up 23% On Immunotherapy Trial Update

Greenwich LifeSciences (GLSI) shares rose 23% to $16.92 after the company announced two abstracts from its Phase III FLAMINGO-01 breast cancer immunotherapy trial were accepted for the 2026 SABCS. The stock's 52-week range is $7.78 to $34.10.

Original reporting
Published Nov 17, 2026, 4:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 6:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$GLSI
Bullish
medium confidence
Mentioned
$GLSI
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$GLSIBullishMed
01

Why it matters

The acceptance of two Phase III abstracts for SABCS provides a credible, near-term visibility boost and can catalyze additional speculative positioning until the December 9 poster details are available online.

02

Market read

Traders can treat this as a momentum catalyst with a defined next milestone (Dec 9 poster presentation), but without endpoint data in the article.

03

What to watch

The article does not provide efficacy or safety numbers, so follow-through may depend on what the posters actually show and whether SABCS approval affects timing or content.

Relevance 7/10Novelty 6/10Timing: today’s session momentum tied to SABCS abstract acceptance; next event flagged for Dec 9, 2026

Background

GLSI is evaluating GLSI-100 (GP2) in its Phase III FLAMINGO-01 breast cancer immunotherapy trial, with FDA Fast Track status mentioned.

Company-level read

Ticker impact

$GLSIBullishMedium confidence
Context

Greenwich LifeSciences shares jumped after two Phase III FLAMINGO-01 breast cancer immunotherapy abstracts were accepted for SABCS publication.

Expected impact

Likely continued upside pressure as traders price in improved clinical narrative ahead of the December 9 poster presentation.

Evidence & confidence

The article reports a same-day, company-specific clinical-trial publication acceptance and ties it to its FDA Fast Track immunotherapy program, which typically supports sentiment even without full efficacy details.

Market effects

Supports sentiment for breast cancer immunotherapy and Phase III biotech development pipelines, though it is not broad-sector guidance.

Limited, primarily affects US small/mid-cap biotech sentiment rather than macro regional flows.

Low; SABCS is international, but the disclosure is company-specific and not a global policy or regulatory shift.

Counterpoint

Abstract acceptance is not the same as full peer-reviewed efficacy results; the market may overreact until detailed endpoints are disclosed.

Key entities

  • Greenwich LifeSciences, Inc.

    Subject of the article; shares rose on acceptance of Phase III FLAMINGO-01 abstracts for SABCS publication.

  • FLAMINGO-01

    Phase III breast cancer immunotherapy trial referenced as the source of the SABCS abstracts.

  • GLSI-100 (GP2)

    Immunotherapy candidate evaluated in FLAMINGO-01; described as FDA Fast Track.

  • San Antonio Breast Cancer Symposium (SABCS)

    Conference where the Phase III posters are accepted for publication and presentation.

Related articles

$GLSIMedAI 8/10

RedChip Companies, Inc.: Greenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

Greenwich LifeSciences (GLSI) will be featured on the RedChip Small Stocks, Big Money show on Bloomberg TV and CNBC. CEO Snehal Patel discusses GLSI-100, an immunotherapy for HER2-positive breast cancer, highlighting an 80% reduction in recurrence in trials. The company is expanding its Phase III trial and exploring broader patient eligibility. GLSI aims to double its target population to 88,000 patients in the U.S. and Europe.

$GLSIMedAI 8/10

Greenwich LifeSciences presents at BIO-Europe 2026 in Cologne

Greenwich LifeSciences (GLSI) presented at BIO-Europe 2026, discussing its phase three trial (Flamingo-1) for early breast cancer. The trial, led by Baylor College of Medicine, has 180 sites in the US and Europe, with plans to expand. The company reported an 80% reduction in recurrence rate in phase two trials. GLSI is publicly traded, has raised $60M since IPO, and is fast track designated. Management owns 75-85% of the company, with a low float and extended lockup until January 2027.

$GLSIMedAI 8/10

Greenwich Advances FLAMINGO-01 Phase III Trial With Strategic Enrollment Changes

Greenwich LifeSciences (GLSI) said U.S. and European regulators approved changes to its FLAMINGO-01 Phase III trial of GLSI-100 for breast cancer recurrence. The DSMB recommended continuing without changes. Enrollment now includes non-HLA-A*02 patients, expected to more than double enrollment rate. In a 250-patient arm, preliminary results show a 70-80% recurrence reduction. Cash was about $8.9M at June 30, 2026.